Patent classifications
A61K39/4641
TUMORICIDAL AND ANTIMICROBIAL COMPOSITIONS AND METHODS
Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.
Tumoricidal and antimicrobial compositions and methods
Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.
METHODS OF EXPANDING MYELOID CELL POPULATIONS AND USES THEREOF
The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and/or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation.
USE OF PLA2G5-DEFICIENT SUPPRESSIVE MACROPHAGES IN SUPPRESSION OF INFLAMMATION
Methods to reduce the inflammatory response critical in the pathogenesis of asthma and asthma exacerbations via the introduction of autologous Pla2g5-deficient suppressive macrophages into the airways of patients with asthma.
ADOPTIVE T CELL THERAPY
The present disclosure provides a composition comprising isolated T cells, wherein the T cells have specificity against a range of clinical fungal pathogens.
Tumoricidal and antimicrobial compositions and methods
Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.
Methods for treating chronic lymphocytic leukemia (CLL)
The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.
GENETICALLY ENGINEERED CELL-DERIVED VACCINES
The disclosure provides for compositions and methods comprising cell-derived vesicles induced from cells that have been genetically engineered or infected to express specific antigen(s), and uses thereof, including as a cell-free, cell-like vaccine.
TUMORICIDAL AND ANTIMICROBIAL COMPOSITIONS AND METHODS
Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.